Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Carcinoma 2Prostatic Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 6pembrolizumab 4durvalumab 4Platinum 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4cemiplimab 3Radiation 3Paclitaxel 3Cetuximab 3Biopsy 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Pemetrexed 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1repotrectinib 1poly ICLC 1ipatasertib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × ALT-803 × 30 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07574541 2026-06-05

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡